UniQure N.V.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Amsterdam Netherlands (1998)

Organization Overview

First Clinical Trial
2012
NCT02082860
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

UniQure Biopharma B.V. | uniQure France SAS

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemophilia A (Phase 3)

Hemophilia B (Phase 3)

Huntington Disease (Phase 2)

Hyperlipoproteinemia Type I (Phase 2)

Mucopolysaccharidosis III (Phase 2)

Porphyria, Acute Intermittent (Phase 1)

Porphyria, Erythropoietic (Phase 1)

Porphyrias (Phase 1)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 12